argenx combines the diversity of the llama immune system with antibody engineering, advancing a clinical pipeline to treat patients with cancer and severe autoimmune diseases. Their platforms allow argenx to unlock novel and complex targets and develop antibody-based drugs designed for greater efficacy and longer duration of effect. Llamas’ antibodies are about 90 percent smaller than the antibodies of humans, allowing the immune system fighters to better target invading bacteria and viruses.